S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(19)32556-5 ◽

2019 ◽

Vol 394 (10214) ◽

pp. 2096-2107 ◽

Cited By ~ 76

Author(s):

Michel Attal ◽

Paul G Richardson ◽

S Vincent Rajkumar ◽

Jesus San-Miguel ◽

Meral Beksac ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718100766.793522195 ◽

2016 ◽

Author(s):

Parameswaran Hari ◽

Binod Dhakal

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

High Dose ◽

Open Label ◽

Phase 3 ◽

High Dose Dexamethasone ◽

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps8070 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS8070-TPS8070 ◽

Cited By ~ 4

Author(s):

Jatin J. Shah ◽

Sundar Jagannath ◽

María-Victoria Mateos ◽

Antonio Palumbo ◽

Uma Kher ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Annals of Oncology ◽

10.1093/annonc/mdw525.50 ◽

2016 ◽

Vol 27 ◽

pp. viii15-viii16

Author(s):

M.V. Mateos ◽

H. Blacklock ◽

A.O. Rocafiguera ◽

S. Iida ◽

S. Jagannath ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Open Label ◽

Phase 3 ◽

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70380-2 ◽

2013 ◽

Vol 14 (11) ◽

pp. 1055-1066 ◽

Cited By ~ 454

Author(s):

Jesus San Miguel ◽

Katja Weisel ◽

Philippe Moreau ◽

Martha Lacy ◽

Kevin Song ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

High Dose ◽

Open Label ◽

Phase 3 ◽

High Dose Dexamethasone ◽

CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.142 ◽

2017 ◽

Vol 17 ◽

pp. S330 ◽

Cited By ~ 1

Author(s):

Sagar Lonial ◽

Paul Richardson ◽

Donna Reece ◽

Hesham Mohamed ◽

Suresh Shelat ◽

...

Keyword(s):

Multiple Myeloma ◽

Randomized Trial ◽

Open Label ◽

Phase 3 ◽

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1747066 ◽

2020 ◽

Vol 61 (8) ◽

pp. 1850-1859

Author(s):

Katja Weisel ◽

Meletios Dimopoulos ◽

Philippe Moreau ◽

Munci Yagci ◽

Alessandra Larocca ◽

...

Keyword(s):

Quality Of Life ◽

Multiple Myeloma ◽

Low Dose ◽

Health Related Quality ◽

Phase 3 ◽

Related Quality ◽

Health Related

Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

Annals of Oncology ◽

10.1093/annonc/mdw375.36 ◽

2016 ◽

Vol 27 ◽

pp. vi324 ◽

Cited By ~ 2

Author(s):

E.M. Ocio ◽

J. Shah ◽

S. Jagannath ◽

M.-V. Mateos ◽

A. Palumbo ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Phase 3 ◽

MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps8610 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS8610-TPS8610 ◽

Cited By ~ 6

Author(s):

Paul G. Richardson ◽

Amine Bensmaine ◽

Thomas Doerr ◽

Jianming Wang ◽

Mohamed H. Zaki ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Efficacy And Safety ◽

Phase 3 ◽

Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.8001 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 8001-8001 ◽

Cited By ~ 14

Author(s):

Paul G. Richardson ◽

Albert Oriol Rocafiguera ◽

Meral Beksac ◽

Anna Marina Liberati ◽

Monica Galli ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Phase 3 ◽